ID   BCWM.1
AC   CVCL_A035
SY   BCWM-1; BCWM_1; BCWM1; Bing Center for Waldenstrom's Macroglobulinemia.1
DR   BTO; BTO:0005177
DR   CLO; CLO_0009833
DR   cancercelllines; CVCL_A035
DR   Cosmic; 1762456
DR   Cosmic; 2645642
DR   LINCS_HMS; 51097
DR   LINCS_LDP; LCL-2094
DR   Wikidata; Q54795725
RX   PubMed=17761288;
RX   PubMed=18650470;
RX   PubMed=22950966;
RX   PubMed=23321251;
RX   PubMed=25382610;
RX   PubMed=25853860;
RX   PubMed=28548645;
CC   Doubling time: 3 days (PubMed=17761288).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=23321251).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 16
//
RX   PubMed=17761288; DOI=10.1016/j.exphem.2007.05.022;
RA   Ditzel Santos D., Ho A.W., Tournilhac O., Hatjiharissi E., Leleu X.,
RA   Xu L., Tassone P., Neri P., Hunter Z.R., Chemaly M.A.Z.,
RA   Branagan A.R., Manning R.J., Patterson C.J., Moreau A.-S.,
RA   Ciccarelli B., Adamia S., Kriangkum J., Kutok J.L., Tai Y.-T.,
RA   Zhang J.-W., Pilarski L.M., Anderson K.C., Munshi N.C., Treon S.P.;
RT   "Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia
RT   with productive in vivo engraftment in SCID-hu mice.";
RL   Exp. Hematol. 35:1366-1375(2007).
//
RX   PubMed=18650470; DOI=10.1182/blood-2008-05-154831;
RA   Bergsagel P.L., Kuehl W.M.;
RT   "WSU-WM and BCWM.1 should not be assumed to represent Waldenstrom
RT   macroglobulinemia cell lines.";
RL   Blood 112:917-917(2008).
//
RX   PubMed=22950966; DOI=10.3109/10428194.2012.727418;
RA   Drexler H.G., Chen S., MacLeod R.A.F.;
RT   "Would the real Waldenstrom cell line please stand up?";
RL   Leuk. Lymphoma 54:224-226(2013).
//
RX   PubMed=23321251; DOI=10.1182/blood-2012-09-454355;
RA   Xu L., Hunter Z.R., Yang G., Zhou Y.-S., Cao Y., Liu X., Morra E.,
RA   Trojani A., Greco A., Arcaini L., Varettoni M., Brown J.R., Tai Y.-T.,
RA   Anderson K.C., Munshi N.C., Patterson C.J., Manning R.J.,
RA   Tripsas C.K., Lindeman N.I., Treon S.P.;
RT   "MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M
RT   monoclonal gammopathy, and other B-cell lymphoproliferative disorders
RT   using conventional and quantitative allele-specific polymerase chain
RT   reaction.";
RL   Blood 121:2051-2058(2013).
//
RX   PubMed=25382610; DOI=10.1038/bcj.2014.74;
RA   Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.-K.K.,
RA   Ailawadhi S., Knight J., Heckman M.G., Pinkerton A., Chanan-Khan A.A.;
RT   "Nimbolide targets BCL2 and induces apoptosis in preclinical models of
RT   Waldenstroms macroglobulinemia.";
RL   Blood Cancer J. 4:e260.1-e260.10(2014).
//
RX   PubMed=25853860; DOI=10.1371/journal.pone.0122338;
RA   Paulus A., Chitta K.S., Wallace P.K., Advani P.P., Akhtar S.,
RA   Kuranz-Blake M., Ailawadhi S., Chanan-Khan A.A.;
RT   "Immunophenotyping of Waldenstroms macroglobulinemia cell lines
RT   reveals distinct patterns of surface antigen expression: potential
RT   biological and therapeutic implications.";
RL   PLoS ONE 10:E0122338-E0122338(2015).
//
RX   PubMed=28548645; DOI=10.1038/bcj.2017.40;
RA   Paulus A., Akhtar S., Yousaf H., Manna A., Paulus S.M., Bashir Y.,
RA   Caulfield T.R., Kuranz-Blake M., Chitta K.S., Wang X., Asmann Y.,
RA   Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.;
RT   "Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or
RT   CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through
RT   upregulation of Bcl-2 and AKT resulting in vulnerability towards
RT   venetoclax or MK2206 treatment.";
RL   Blood Cancer J. 7:e565.1-e565.11(2017).
//